Format

Send to

Choose Destination
Bioorg Med Chem. 2016 May 1;24(9):1937-80. doi: 10.1016/j.bmc.2016.03.004. Epub 2016 Mar 9.

Synthetic approaches to the 2014 new drugs.

Author information

1
Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, CT 06340, United States. Electronic address: andrew.flick@pfizer.com.
2
Pharmacodia (Beijing) Co., Ltd, Beijing 100085, China. Electronic address: Sheryl.ding@pharmacodia.com.
3
Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, CT 06340, United States. Electronic address: carolyn.a.leverett@pfizer.com.
4
Celgene Avilomics Research, 200 Cambridge Park Drive, Cambridge, MA 02140, United States. Electronic address: rkyne@celgene.com.
5
China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai 200131, China. Electronic address: kevin.liu@novartis.com.
6
BioDuro Co., Ltd, Shanghai 200131, China. Electronic address: sarah.fink@bioduro.com.
7
Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, CT 06340, United States. Electronic address: christopher.j.odonnell@pfizer.com.

Abstract

New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.

KEYWORDS:

Medicine; New chemical entities; New drug molecules; Synthesis; Therapeutic agents

PMID:
27020685
DOI:
10.1016/j.bmc.2016.03.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center